Commonly prescribed antipsychotic medications used to treat Alzheimer?s patients with delusions, aggression, hallucinations, and other similar symptoms can benefit some patients, but they appear to be no more effective than a placebo when adverse side effects are considered, according to the first phase of a large-scale clinical trial funded by the National Institutes of Health?s National Institute of Mental Health (NIMH). The trial, known as the Clinical Antipsychotic Trial of Intervention Effectiveness study for Alzheimer?s disease (CATIE-AD), was published in the October 12, 2006, issue of the New England Journal of Medicine.